MNMD.Q

Episode 2 Earlier this year Mindmed (MNMD.Q) co-founder JR Rahn went on an epic selling spree, selling nearly 90% of his holdings without telling the public why until days…
“In business, cash is oxygen” – Gary Vaynerchuk   Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Studying clinical studies For many psychedelics companies, clinical trials are the most expensive part of their business model and the reason they need to raise so much capital. Finding…
Mind Medicine (MNMD.Q, MMED.NE) announced that they have agreed to partner with Forian (FORA.Q), who provide evidence-based support for clinical and commercial decision making. Forian and MindMed will collaborate…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
MindMed (MNMD.Q) will participate and assist in the financing of the Digital Medicine Society’s (DiMe) Digital Health Measurement Collaborative Community (DATAcc) in the development of best practices, and the…
MindMed (MMED.NE, MNMD.Q) announced the start of a Phase 1 trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT. DMT, properly known as N,N-Dimethyltryptamine is a psychoactive chemical…
MindMed (MNMD.Q) and healthcare data consolidator Datavant, announced a partnership wherein MindMed will make use of Datavant’s tech to link their clinical trial data to external data from both…
MindMed (MNMD.Q) announced they are appointing Dr. Maurizio Fava to their Scientific Advisory Board. Dr. Fava obtained his medical doctorate from the University of Padova School of Medicine, and went…